Jian Yu

List of Publications by Citations

60 papers	1,459 citations	20 h-index	38 g-index
67 ext. papers	1,783 ext. citations	4.7 avg, IF	4.46 L-index

#	Paper	IF	Citations
60	Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 13253-7	11.5	293
59	MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. *Blood*, **2014**, 124, 546-54	2.2	127
58	Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation. *Journal of Clinical Investigation*, **2016**, 126, 585-98	15.9	118
57	Enhanced Multiple Anchoring and Catalytic Conversion of Polysulfides by Amorphous MoS Nanoboxes for High-Performance Li-S Batteries. *Angewandte Chemie - International Edition*, **2020**, 59, 13071-13078	16.4	93
56	Nanoparticle Targeting of Neutrophils for Improved Cancer Immunotherapy. *Advanced Healthcare Materials*, **2016**, 5, 1088-93	10.1	78
55	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. *Blood*, **2016**, 128, 2931-2940	2.2	75
54	Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. *Cell Stem Cell*, **2018**, 22, 951-959.e3	18	75
53	Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 1370-1377	11.5	63
52	Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. *Leukemia*, **2017**, 31, 1333-1339	10.7	57
51	Composition-adjustable Ag-Au substitutional alloy microcages enabling tunable plasmon resonance for ultrasensitive SERS. *Chemical Science*, **2018**, 9, 4009-4015	9.4	53
50	Identification of the gene transcription and apoptosis mediated by TGF-beta-Smad2/3-Smad4 signaling. *Journal of Cellular Physiology*, **2008**, 215, 422-33	7	46
49	Complementary analysis of microRNA and mRNA expression during phorbol 12-myristate 13-acetate (TPA)-induced differentiation of HL-60 cells. *Biotechnology Letters*, **2008**, 30, 2045-52	3	41
48	Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells. *Leukemia*, **2017**, 31, 2615-2622	10.7	37
47	Identification of activity-dependent gene expression profiles reveals specific subsets of genes induced by different routes of Ca(2+) entry in cultured rat cortical neurons. *Journal of Cellular Physiology*, **2007**, 212, 126-36	7	31
46	Wnt5a induces ROR1 to associate with 14-3-3 for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells. *Leukemia*, **2017**, 31, 2608-2614	10.7	28
45	Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. *Blood*, **2018**, 132, 170-178	2.2	28
44	Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. *Biotechnology Letters*, **2009**, 31, 487-94	3	26

43	Structure-activity studies of antitumor agent irofulven (hydroxymethylacylfulvene) and analogues. *Journal of Organic Chemistry*, **2001**, 66, 6158-63	4.2	24
42	Non-intrusive reduced-order modeling for fluid problems: A brief review. *Proceedings of the Institution of Mechanical Engineers, Part G: Journal of Aerospace Engineering*, **2019**, 233, 5896-5912	0.9	24
41	Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-B to repress autocrine STAT3 activation in chronic lymphocytic leukemia. *Blood*, **2019**, 134, 1084-1094	2.2	22
40	Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells. *Leukemia*, **2019**, 33, 653-661	10.7	19
39	Clinical features and phylogenetic analysis of severe hand-foot-and-mouth disease caused by Coxsackievirus A6. *Infection, Genetics and Evolution*, **2020**, 77, 104054	4.5	14
38	Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. *Oncotarget*, **2018**, 9, 24731-24736	3.3	12
37	Morphological and structural engineering in amorphous Cu2MoS4 nanocages for remarkable electrocatalytic hydrogen evolution. *Science China Materials*, **2019**, 62, 1275-1284	7.1	10
36	Amorphous Mn O Nanocages with High-Efficiency Charge Transfer for Enhancing Electro-Optic Properties of Liquid Crystals. *Small*, **2019**, 15, e1805475	11	6
35	On the use of the discontinuous Galerkin method for numerical simulation of two-dimensional compressible turbulence with shocks. *Science China: Physics, Mechanics and Astronomy*, **2014**, 57, 1758-1770	3.6	6
34	Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo. *Pharmacological Research*, **2020**, 151, 104512	10.2	6
33	Enhanced Multiple Anchoring and Catalytic Conversion of Polysulfides by Amorphous MoS3 Nanoboxes for High-Performance Li-S Batteries. *Angewandte Chemie*, **2020**, 132, 13171-13178	3.6	4
32	A new high-accuracy scheme for compressible turbulent flows. *International Journal of Computational Fluid Dynamics*, **2017**, 31, 362-378	1.2	4
31	Implicit high-order discontinuous Galerkin method with HWENO type limiters for steady viscous flow simulations. *Acta Mechanica Sinica/Lixue Xuebao*, **2013**, 29, 526-533	2	3
30	Practical aspects of p-multigrid discontinuous Galerkin solver for steady and unsteady RANS simulations. *International Journal for Numerical Methods in Fluids*, **2015**, 78, 670-690	1.9	3
29	Hermite WENO-based limiters for high order discontinuous Galerkin method on unstructured grids. *Acta Mechanica Sinica/Lixue Xuebao*, **2012**, 28, 241-252	2	3
28	Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies. *BioMed Research International*, **2020**, 2020, 4956946	3	3
27	Designing Several Types of Oscillation-Less and High-Resolution Hybrid Schemes on Block-Structured Grids. *Communications in Computational Physics*, **2017**, 21, 1376-1407	2.4	2
26	High-order discontinuous Galerkin solver on hybrid anisotropic meshes for laminar and turbulent simulations. *Applied Mathematics and Mechanics (English Edition)*, **2014**, 35, 799-812	3.2	2

25	Abstract 950: Selective cytotoxicity of A6 peptide against ZAP-70 expressing CLL B-cells **2014**,		2
24	Wnt5a Induces ROR1 to Complex with HS1, Which Undergoes Tyrosine Phosphorylation and Contributes to Planar-Cell-Polarity Migration in Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 301-301	2.2	2
23	Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab. *Blood*, **2017**, 130, 829-829	2.2	2
22	Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies. *BioMed Research International*, **2020**, 2020, 4241864	3	2
21	Suitability of artificial viscosity discontinuous Galerkin method for compressible turbulence. *Science China Technological Sciences*, **2017**, 60, 1032-1049	3.5	1
20	High accuracy schemes for compressible turbulence simulations **2017**,		1
19	Assessment of shock capturing schemes for discontinuous Galerkin method. *Applied Mathematics and Mechanics (English Edition)*, **2014**, 35, 1361-1374	3.2	1
18	Agelastatin A (AgA), a Marine Sponge Derived Alkaloid, Inhibits Wnt/Beta-Catenin Signaling and Selectively Induces Apoptosis in Chronic Lymphocytic Leukemia Independently of p53. *Blood*, **2011**, 118, 1786-1786	2.2	1
17	Human ROR1 Activates AKT and Accelerates Leukemia Cell Proliferation. *Blood*, **2012**, 120, 3872-3872	2.2	1
16	Preclinical Development Of ROR1 Peptide Based Vaccine With Activity Against Chronic Lymphocytic Leukemia In ROR1 Transgenic Mice. *Blood*, **2013**, 122, 4174-4174	2.2	1
15	High-Level Expression of ROR1 Associates with Early Disease Progression in Patients with Chronic Lymphocytic Leukemia. *Blood*, **2015**, 126, 1713-1713	2.2	1
14	Cirmtuzumab Targets ROR1 to Inhibit Ibrutinib-Resistant, Wnt5a-Induced Rac1 Activation in Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 2034-2034	2.2	1
13	Immunotherapeutic Targeting of ROR1-Dependent, Non-Canonical Wnt5a-Signaling By Cirmtuzumab: A First-in-Human Phase I Trial for Patients with Intractable Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 3224-3224	2.2	1
12	Wnt5a Induces Association of ROR1 with 14-3-3□to Enhance Chemotaxis and Proliferation in Chronic Lymphocytic Leukemia. *Blood*, **2016**, 128, 349-349	2.2	1
11	Electroporation of CRISPR-Cas9 into Malignant B Cells for Loss-of-Function Studies of Target Gene Via Knockout. *Methods in Molecular Biology*, **2020**, 2050, 85-90	1.4	1
10	Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression. *Microbial Cell Factories*, **2021**, 20, 67	6.4	1
9	A colloidal gold-based immunochromatographic strip for rapid detection of SARS-CoV-2 antibodies after vaccination. *Medicine in Novel Technology and Devices*, **2021**, 11, 100084	2.1	1
8	Wnt5a Induces Association of ROR1 with Ca2+/Calmodulin-Dependent Protein Kinase II and ROR1-Dependent Calcium Influx in Chronic Lymphocytic Leukemia. *Blood*, **2018**, 132, 1846-1846	2.2	0

List of Publications

7	Distinct BTK inhibitors differentially induce apoptosis but similarly suppress chemotaxis and lipid accumulation in mantle cell lymphoma. *BMC Cancer*, **2021**, 21, 732	4.8	0
6	Revisit of dilation-based shock capturing for discontinuous Galerkin methods. *Applied Mathematics and Mechanics (English Edition)*, **2018**, 39, 379-394	3.2	0
5	FLT3 Ligand-DM1 Conjugate Selectively Targets Acute Myeloid Leukemia Cells with FLT3 Expression. *Blood*, **2020**, 136, 30-31	2.2	
4	Cirmtuzumab Blocks Production of Proinflammatory Factors By Inhibiting Wnt5a/ROR1 Induced Activation of NF-Kappa B in Chronic Lymphocytic Leukemia. *Blood*, **2018**, 132, 4415-4415	2.2	
3	Structural Features of ROR1 Required for Complexing with ROR2 and Enhancing Chemokine-Induced Migration and Leukemia-Cell Proliferation, Which Can be Blocked By the Anti-ROR1 Mab Cirmtuzumab (UC-961). *Blood*, **2015**, 126, 1741-1741	2.2	
2	Targeting of Chronic Lymphocytic Leukemia B Cells with a Novel Monoclonal Antibody to ROR1. *Blood*, **2011**, 118, 984-984	2.2	
1	Targeting Of Chronic Lymphocytic Leukemia B Cells With a Humanized Monoclonal Antibody Specific For ROR1. *Blood*, **2013**, 122, 2873-2873	2.2	